Learn more about the Knowledge Center Service

The Pediatric Tuberculosis Treatment Pipeline: Beyond Pharmacokinetics and Safety Data

by Lindsay McKenna

Jan 15, 2020

The roster of enrolling and planned pediatric tuberculosis (TB) treatment studies is growing. Emerging results from pharmacokinetics (PK) and safety studies continue to inform optimal dosing strategies in children and to highlight areas in need of further investigation. New pediatric formulations continue to advance to market, and consensus has begun to form around the need for efficacy studies of simplified multidrug-resistant TB (MDR-TB) treatment regimens in children.

The Pediatric Tuberculosis Treatment Pipeline: Beyond Pharmacokinetics and Safety Data